Denali Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating
Analyst Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price target at ...
Denali Gains 26.6% in a Year: How Should You Play the Stock?
DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost. However, recent pipeline setbacks warrant caution.
Nasdaq6d
Denali Gains 26.6% in a Year: How Should You Play the Stock?
Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained 26.6% against the industry’s decline of 14.3%. The stock has also ...
Nasdaq5d
DNLI Makes Bullish Cross Above Critical Moving Average
In trading on Tuesday, shares of Denali Therapeutics Inc (Symbol: DNLI) crossed above their 200 day moving average of $23.11, changing hands as high as $23.33 per share. Denali Therapeutics Inc ...
BioSpace4d
FDA Tacks Boxed Warning on Teva’s Copaxone, Other MS Drugs
The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...
Forbes6d
Trump Renames Denali To Mount McKinley—Here’s What To Know
President Donald Trump signed an executive order Monday renaming Denali—the highest peak in North America—to Mount McKinley, the Alaska mountain’s name prior to 2015, a move he has suggested ...
Seattle Times4d
Denali versus McKinley: a brief history of the debate over a mountain’s name
At 20,310 feet tall, Denali is visible for hundreds of miles around. For thousands of years, it has been called not just Denali but a variety of names by Alaska Native people living around the ...